Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reg reconstitution after transplant-Reference-Cited by-同舟云学术

Combined OX40L and mTOR blockade controls effector T cell activation while preserving T reg reconstitution after transplant

Published:2017-09-20 Issue:408 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Tkachev Victor¹^ORCID,Furlan Scott N.¹²³,Watkins Benjamin¹⁴,Hunt Daniel J.¹,Zheng Hengqi Betty¹^ORCID,Panoskaltsis-Mortari Angela⁵^ORCID,Betz Kayla¹,Brown Melanie¹,Schell John B.¹^ORCID,Zeleski Katie¹^ORCID,Yu Alison¹^ORCID,Kirby Ian⁶,Cooley Sarah⁵,Miller Jeffrey S.⁵,Blazar Bruce R.⁵^ORCID,Casson Duncan⁶^ORCID,Bland-Ward Phil⁶,Kean Leslie S.¹²³^ORCID

Affiliation:

1. Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, WA 98101, USA.

2. Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.

3. Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

4. Emory University School of Medicine, Atlanta, GA 30322, USA.

5. Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55454, USA.

6. Kymab Ltd., Cambridge CB22 3AT, UK.

Abstract

OX40L blockade synergizes with sirolimus to prevent GVHD by controlling effector T cell activation while supporting T reg reconstitution.

Funder

National Heart, Lung, and Blood Institute

National Institute of Allergy and Infectious Diseases